Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Senetek PLC - SNTKY Breaks out to new high -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (731)	8/7/2002 8:21:01 PM
From: SemiBull	Respond to of 737

New Study Forecasts Peak-Year Sales of $50 - $100 Million for Senetek PLC's Invicorp(TM) Treatment for Erectile Dysfunction NAPA, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Senetek PLC (Nasdaq: SNTK - News), www.senetekplc.com, a biopharmaceutical company focused on developing and co-marketing products in the key skincare/dermatologicals and sexual dysfunction categories worldwide, announced today that a new independent study of the erectile dysfunction (ED) market by Decision Resources, Inc. -- a worldwide leader in pharmaceutical research publications -- forecasts peak-year sales of $50 to $100 million for Senetek PLC's Invicorp(TM) treatment for ED. "Erectile Dysfunction, July 2002," a new study published by Decision Resources, Waltham, Massachusetts, examines current treatments for ED and evaluates the potential of emerging ED therapies. According to the study, novel treatments with improved compound attributes will continue to expand the ED market. Faster onset of action, longer duration of action, and fewer side effects are all unmet needs that emerging therapies are expected to address and subsequently drive the ED market. The study further states that Injectable and Transurethal Agents will enjoy renewed growth during the forecast periods (2001 - 2006 & 2006 - 2011), benefiting from the availability of less invasive (microinjection) local therapy and from increases in the diagnosed population. Injectable and transurethal agents will continue to help those patients who need drug treatment for ED but are contraindicated for phosphodiesterase (PDE) inhibitors. The study reports on Senetek's Invicorp(TM) treatment for Erectile Dysfunction as a product having a novel microinjection system that significantly reduces the pain associated with local invasive ED therapies. The researchers believe, "this less painful system will be a major advantage over alprostadil injections, and Invicorp(TM) will assume a dominant position in the injectable/transurethal category, where it will capture an 80% share in 2011". Current therapies available in the injectable/transurethal category include Pharmacia's Caverject®, Schwarz Pharma's Edex/Viridal®, Asta Medica's Icavex® and Vivus' Muse®. Visit Senetek PLC's web site: senetekplc.com . Safe Harbor Statement: This press release and Web site contain certain forward-looking statements, including statements as to the Company's expectations concerning continued improvement in financial results, achieving broadened product offerings by Kinetin licensees, negotiating new licensing agreements, receiving product approval for Invicorp(TM) in key European markets, and achieving other significant business developments. Forward-looking statements by their nature involve substantial uncertainties and actual results may differ materially from those expressed in such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2001 and its Quarterly Report on Form 10-Q for the three months ended March 31, 2002, but the Company can give no assurance that it has identified all of the factors that may result in any particular forward-looking statement materially differing from actual results and assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise. SOURCE: Senetek PLC